Literature DB >> 23362314

Kidney disease and increased mortality risk in type 2 diabetes.

Maryam Afkarian1, Michael C Sachs, Bryan Kestenbaum, Irl B Hirsch, Katherine R Tuttle, Jonathan Himmelfarb, Ian H de Boer.   

Abstract

Type 2 diabetes associates with increased risk of mortality, but how kidney disease contributes to this mortality risk among individuals with type 2 diabetes is not completely understood. Here, we examined 10-year cumulative mortality by diabetes and kidney disease status for 15,046 participants in the Third National Health and Nutrition Examination Survey (NHANES III) by linking baseline data from NHANES III with the National Death Index. Kidney disease, defined as urinary albumin/creatinine ratio ≥30 mg/g and/or estimated GFR ≤60 ml/min per 1.73 m(2), was present in 9.4% and 42.3% of individuals without and with type 2 diabetes, respectively. Among people without diabetes or kidney disease (reference group), 10-year cumulative all-cause mortality was 7.7% (95% confidence interval [95% CI], 7.0%-8.3%), standardized to population age, sex, and race. Among individuals with diabetes but without kidney disease, standardized mortality was 11.5% (95% CI, 7.9%-15.2%), representing an absolute risk difference with the reference group of 3.9% (95% CI, 0.1%-7.7%), adjusted for demographics, and 3.4% (95% CI, -0.3% to 7.0%) when further adjusted for smoking, BP, and cholesterol. Among individuals with both diabetes and kidney disease, standardized mortality was 31.1% (95% CI, 24.7%-37.5%), representing an absolute risk difference with the reference group of 23.4% (95% CI, 17.0%-29.9%), adjusted for demographics, and 23.4% (95% CI, 17.2%-29.6%) when further adjusted. We observed similar patterns for cardiovascular and noncardiovascular mortality. In conclusion, those with kidney disease predominantly account for the increased mortality observed in type 2 diabetes.

Entities:  

Mesh:

Year:  2013        PMID: 23362314      PMCID: PMC3559486          DOI: 10.1681/ASN.2012070718

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  28 in total

1.  Synergism and interaction: are they equivalent?

Authors:  W J Blot; N E Day
Journal:  Am J Epidemiol       Date:  1979-07       Impact factor: 4.897

2.  A solid phase fluorescent immunoassay for the measurement of human urinary albumin.

Authors:  B M Chavers; J Simonson; A F Michael
Journal:  Kidney Int       Date:  1984-03       Impact factor: 10.612

3.  In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study.

Authors:  T J Orchard; A M Secrest; R G Miller; T Costacou
Journal:  Diabetologia       Date:  2010-07-28       Impact factor: 10.122

4.  Relation between kidney function, proteinuria, and adverse outcomes.

Authors:  Brenda R Hemmelgarn; Braden J Manns; Anita Lloyd; Matthew T James; Scott Klarenbach; Robert R Quinn; Natasha Wiebe; Marcello Tonelli
Journal:  JAMA       Date:  2010-02-03       Impact factor: 56.272

5.  The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus.

Authors:  K Borch-Johnsen; P K Andersen; T Deckert
Journal:  Diabetologia       Date:  1985-08       Impact factor: 10.122

Review 6.  Albuminuria reflects widespread vascular damage. The Steno hypothesis.

Authors:  T Deckert; B Feldt-Rasmussen; K Borch-Johnsen; T Jensen; A Kofoed-Enevoldsen
Journal:  Diabetologia       Date:  1989-04       Impact factor: 10.122

7.  Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study.

Authors:  P Rossing; P Hougaard; K Borch-Johnsen; H H Parving
Journal:  BMJ       Date:  1996-09-28

8.  Cystatin C, albuminuria, and mortality among older adults with diabetes.

Authors:  Ian H de Boer; Ronit Katz; Jie J Cao; Linda F Fried; Bryan Kestenbaum; Ken Mukamal; Dena E Rifkin; Mark J Sarnak; Michael G Shlipak; David S Siscovick
Journal:  Diabetes Care       Date:  2009-07-08       Impact factor: 19.112

9.  Life expectancy in a large cohort of type 2 diabetes patients treated in primary care (ZODIAC-10).

Authors:  Helen L Lutgers; Esther G Gerrits; Wim J Sluiter; Lielith J Ubink-Veltmaat; Gijs W D Landman; Thera P Links; Reinold O B Gans; Andries J Smit; Henk J G Bilo
Journal:  PLoS One       Date:  2009-08-28       Impact factor: 3.240

10.  Mortality rates in trials of subjects with type 2 diabetes.

Authors:  Ebrahim Barkoudah; Hicham Skali; Hajime Uno; Scott D Solomon; Marc A Pfeffer
Journal:  J Am Heart Assoc       Date:  2012-02-20       Impact factor: 5.501

View more
  327 in total

Review 1.  Smoking as a risk factor for diabetic nephropathy: a meta-analysis.

Authors:  Sensen Su; Wanning Wang; Tao Sun; Fuzhe Ma; Yue Wang; Jia Li; Zhonggao Xu
Journal:  Int Urol Nephrol       Date:  2017-06-19       Impact factor: 2.370

2.  Segmental Sclerosis and Extracapillary Hypercellularity Predict Diabetic ESRD.

Authors:  Amy K Mottl; Adil Gasim; Fernanda Payan Schober; Yichun Hu; Askia K Dunnon; Susan L Hogan; J Charles Jennette
Journal:  J Am Soc Nephrol       Date:  2017-11-27       Impact factor: 10.121

Review 3.  [Diabetic kidney disease - Update 2016].

Authors:  Harald Sourij; Roland Edlinger; Friedrich Prischl; Martin Auinger; Alexandra Kautzky-Willer; Marcus D Säemann; Rudolf Prager; Martin Clodi; Guntram Schernthaner; Gert Mayer; Rainer Oberbauer; Alexander R Rosenkranz
Journal:  Wien Klin Wochenschr       Date:  2016-04       Impact factor: 1.704

Review 4.  Foam cells and the pathogenesis of kidney disease.

Authors:  Minseob Eom; Kelly L Hudkins; Charles E Alpers
Journal:  Curr Opin Nephrol Hypertens       Date:  2015-05       Impact factor: 2.894

5.  Trends in the levels of urine and serum creatinine: data from NHANES 2001-2014.

Authors:  Ram B Jain
Journal:  Environ Sci Pollut Res Int       Date:  2017-03-06       Impact factor: 4.223

6.  Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study.

Authors:  Giuseppe Penno; Anna Solini; Emanuela Orsi; Enzo Bonora; Cecilia Fondelli; Roberto Trevisan; Monica Vedovato; Franco Cavalot; Olga Lamacchia; Marco Scardapane; Antonio Nicolucci; Giuseppe Pugliese
Journal:  Diabetologia       Date:  2018-07-21       Impact factor: 10.122

7.  1,25-(OH)2D3 and its analogue BXL-628 inhibit high glucose-induced activation of RhoA/ROCK pathway in HK-2 cells.

Authors:  Wei Zhang; Bin Yi; Ke Zhang; Aimei Li; Shikun Yang; Jing Huang; Jishi Liu; Hao Zhang
Journal:  Exp Ther Med       Date:  2017-03-09       Impact factor: 2.447

Review 8.  Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes-cardiovascular and renal benefits in patients with chronic kidney disease.

Authors:  Tamara Y Milder; Sophie L Stocker; Dorit Samocha-Bonet; Richard O Day; Jerry R Greenfield
Journal:  Eur J Clin Pharmacol       Date:  2019-08-03       Impact factor: 2.953

Review 9.  Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence.

Authors:  Radica Z Alicic; Emily J Cox; Joshua J Neumiller; Katherine R Tuttle
Journal:  Nat Rev Nephrol       Date:  2020-11-20       Impact factor: 28.314

Review 10.  Therapeutic approaches to diabetic nephropathy--beyond the RAS.

Authors:  Beatriz Fernandez-Fernandez; Alberto Ortiz; Carmen Gomez-Guerrero; Jesus Egido
Journal:  Nat Rev Nephrol       Date:  2014-05-06       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.